ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2022
Outpatient Antifungal Prescribing Patterns in the United States, 2018.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A CRISPR-Cas12a and Quantum-Dot Lateral-Flow Assay for Rapid Species-Level Detection of Trichophyton rubrum.Mycoses · 2026Article
- Burden of non-invasive fungal infections and antifungal therapy in pediatric primary care settings: FUNGICARE Project.Italian journal of pediatrics · 2026Article
- Optimisation of electrospinning parameters to successfully obtain high ratios of medium chain length polyhydroxyalkanoate in electrospun fibres with drug loading for wound healing applications.Journal of materials science. Materials in medicine · 2026Article
- Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix inAntimicrobial agents and chemotherapy · 2025Article
- Antifungal Agents' Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009-2023.Antibiotics (Basel, Switzerland) · 2025Article
- Patient Characteristics, Diagnostic Testing Utilization, and Antifungal Prescribing Pattern for Onychomycosis in the USA: A Cohort Study Using DataDerm, 2016-2022.Skin appendage disorders · 2025Article
- Similarities and distinctions in the activation of themSphere · 2024Article
- Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis.Antimicrobial agents and chemotherapy · 2024Article
- Similarities and distinctions in the activation of thebioRxiv : the preprint server for biology · 2024Article
- Challenges Facing Antimicrobial Stewardship Programs in the Endemic Region for Coccidioidomycosis.Open forum infectious diseases · 2024Review
- An Analysis of the Use of Systemic Antifungals (Fluconazole, Itraconazole, and Terbinafine) in Galicia, Spain, between 2019 and 2022.Diseases (Basel, Switzerland) · 2024Article
- Trends of Azole Antifungal Prescription in the United States: Medicare Part D Provider Utilization and Payment Data Analysis.Open forum infectious diseases · 2023Article
- Evaluation of antifungal use in long-term care facilities using pharmacy dispensing data in the USA, 2019.The Journal of antimicrobial chemotherapy · 2022Article
- Study of Prescription-Indication of Outpatient Systemic Anti-Fungals in a Colombian Population. A Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Widespread inappropriate antibiotic prescribing is a major driver of resistance. Little is known about antifungal prescribing practices in the United States, which is concerning given emerging resistance in fungi, particularly to azole antifungals. Objective: We analyzed outpatient U.S. antifungal prescribing data to inform stewardship efforts. Design: Descriptive analysis of outpatient antifungal prescriptions dispensed during 2018 in the IQVIA Xponent database. Methods: Prescriptions were summarized by drug, sex, age, geography, and healthcare provider specialty. Census denominators were used to calculate prescribing rates among demographic groups. Results: Healthcare providers prescribed 22.4 million antifungal courses in 2018 (68 prescriptions per 1,000 persons). Fluconazole was the most common drug (75%), followed by terbinafine (11%) and nystatin (10%). Prescription rates were higher among females vs. males (110 vs. 25 per 1,000) and adults vs. children (82 vs. 27 per 1,000). Prescription rates were highest in the South (81 per 1,000 persons) and lowest in the West (48 per 1,000 persons). Nurse practitioners and family practitioners prescribed the most antifungals (43% of all prescriptions), but the highest prescribing rates were among obstetrician-gynecologists (84 per provider). Conclusions: Prescribing of antifungal drugs in the outpatient setting was common, with enough courses dispensed for one in every 15 U.S. residents in 2018. Fluconazole use patterns suggest vulvovaginal candidiasis as a common indication. Regional prescribing differences could reflect inappropriate use or variations in disease burden. Further study of higher antifungal use in the South could help target antifungal stewardship practices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.